Mycobacterial Lipoprotein Z Triggers Efficient Innate and Adaptive Immunity for Protection Against Mycobacterium tuberculosis Infection

Yingying Chen, Jia-ni Xiao, Yong Li, Yang-jiong Xiao, Yanqing Xiong, Ying Liu, Shujun Wang, Ping Ji, Guoping Zhao, Hao Shen, Shuihua Lu, Xiao‐Yong Fan, Ying WangFrontiers in Immunology 2019 · DOI

Abstract

Mycobacterial lipoproteins are involved in both virulence and immunoregulatory processes during Mycobacterium tuberculosis (M.tb) infection. In previous investigations of over 30 M.tb proteins, mycobacterial lipoprotein Z (LppZ) was identified as a highly immune-dominant antigen. This study explores how LppZ triggers immune responses using murine air pouch and M.tb infection models. Results show that LppZ recruits inflammatory cells and induces proinflammatory cytokines. Furthermore, LppZ immunization induces strong Th1 responses and confers protection against the virulent H37Rv strain at levels comparable to BCG, but with significantly less pathological lung damage. Protection is linked to LppZ-specific polyfunctional CD4<sup>+</sup> T cells capable of secreting IFN-γ, IL-2, and TNF-α. These findings highlight LppZ's strong immunogenicity and its potential as a candidate for TB vaccine development.

Introduction

Tuberculosis (TB) remains a leading cause of death from infectious disease globally. The standard Bacille Calmette-Guérin (BCG) vaccine, while effective in children, shows inconsistent protection against pulmonary TB in adults. The search for novel vaccine candidates is often limited by a narrow focus on a few well-known antigens. This research focuses on LppZ, a protein identified as highly reactive in TB patients, to determine if it can effectively bridge innate and adaptive immune responses to provide superior protection.

Methods

The study employed a multi-stage experimental design:

  • Clinical Immunoreactivity: ELISpot assays were used to measure IFN-γ responses to LppZ in 86 TB patients and 48 healthy controls, comparing it to the standard E6C10 (ESAT6-CFP10) antigen.
  • Innate Response Modeling: A murine air pouch model was used to observe the immediate recruitment of neutrophils and macrophages and the secretion of cytokines in response to LppZ.
  • Vaccination and Challenge: Mice were immunized with recombinant LppZ (adjuvanted with DDA/MPL) and subsequently challenged with aerosolized M.tb H37Rv. Bacterial loads (CFU) and histopathological lung scores were recorded.
  • Polyfunctional T-Cell Analysis: Flow cytometry was used to identify CD4+ T cells in the lungs capable of producing multiple cytokines (IFN-γ, IL-2, and TNF-α) simultaneously.

Key Results

LppZ as a Dominant Human Antigen

Clinical data confirmed that LppZ is a primary target for the human immune system during natural infection. LppZ-specific T-cell responses were as robust as those elicited by the gold-standard E6C10 antigen.

LppZ immunoreactivity and diagnostic performance in human TB patients compared to E6C10.

As illustrated in Figure 5, LppZ-specific IFN-γ responses effectively discriminated TB patients from healthy controls with an Area Under the Curve (AUC) of 0.8739. This diagnostic performance reached 50% sensitivity and 97.92% specificity, confirming its high immunogenicity in humans.

Protective Efficacy and Reduced Pathology

In mouse models, LppZ demonstrated a unique ability to act as an "innate-adaptive bridge," recruiting inflammatory cells directly. Following challenge with virulent M.tb, LppZ-immunized mice showed a significant reduction in bacterial load (~4.5 Log10 CFU) compared to controls (~5.0 Log10 CFU), approaching the efficacy of BCG (~4.1 Log10 CFU).

Notably, LppZ vaccination resulted in significantly less lung tissue damage than the adjuvant-only control. Pathological scoring indicated that LppZ-mediated immunity is more "surgical," providing protection without the extensive inflammatory consolidation often seen in TB infection.

Induction of Polyfunctional T Cells

The protective effect was associated with the presence of polyfunctional CD4+ T cells in the lungs. These cells, which secrete IFN-γ, IL-2, and TNF-α, are considered the most effective T-cell subset for controlling M.tb infection.

Discussion and Future Directions

LppZ is a potent immunogen that triggers both innate danger signals and high-quality adaptive cellular immunity. Its ability to match BCG's protective levels while minimizing lung pathology makes it a highly attractive candidate for future TB vaccine strategies, potentially as a booster to BCG.

Future research should address the durability of this immune memory and evaluate LppZ's performance across different delivery platforms, such as viral vectors or lipid nanoparticles. Additionally, while the mouse model is informative, further studies in non-human primates may be necessary to better understand LppZ's impact on human-like granuloma formation.

Summary updated

Abstract

Mycobacterial lipoproteins are considered to be involved in both virulence and immunoregulatory processes during <i>Mycobacterium tuberculosis</i> (<i>M.tb</i>) infection. In our previous investigations on the immunoreactivity of more than 30 <i>M.tb</i> proteins in active TB patients, we identified mycobacterial lipoprotein Z (LppZ) as one of the most immune dominant antigens. How LppZ triggers immune responses is still unclear. In this study, we analyzed LppZ-mediated innate and adaptive immunity using a murine air pouch model and an <i>M.tb</i> infection model, respectively. We found that LppZ could not only recruit inflammatory cells but also induce the production of proinflammatory cytokines inside the pouches. LppZ could also induce strong Th1 responses following immunization and confer protection against challenge with <i>M.tb</i> virulent strain H37Rv at a similar level to BCG vaccination but with less pathological damage in the lungs. Furthermore, we revealed the presence of LppZ-specific functional CD4<sup>+</sup> T cells in the lungs of the challenged mice that were capable of secreting double or triple cytokines, including IFN-γ, IL-2, and TNF-α. Our study thus demonstrates that LppZ is of strong immunogenicity during <i>M.tb</i> infection in both humans and mice and has the ability to trigger effective innate and cellular immunity. Considering the limitations of candidate antigens in the pipeline of TB vaccine development, LppZ-mediated immune protection against <i>M.tb</i> challenge in the mouse model implies its potential application in vaccine development.
BibTeX
@inproceedings{chen2019mycobacterial,
  author = {Yingying Chen and Jia-ni Xiao and Yong Li and Yang-jiong Xiao and Yanqing Xiong and Ying Liu and Shujun Wang and Ping Ji and Guoping Zhao and Hao Shen and Shuihua Lu and Xiao‐Yong Fan and Ying Wang},
  title = {{Mycobacterial Lipoprotein Z Triggers Efficient Innate and Adaptive Immunity for Protection Against Mycobacterium tuberculosis Infection}},
  booktitle = {Frontiers in Immunology},
  year = {2019},
  doi = {10.3389/fimmu.2018.03190},
}
Figure